FIELD: chemistry.
SUBSTANCE: invention relates to hybrid coumarins of formula 1–3 having an anticoagulant activity of indirect action.
EFFECT: new compounds have been obtained that can be used in medicine in the treatment of cardiovascular diseases.
1 cl, 10 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICOAGULANT AGENT OF INDIRECTLY ACTION BASED ON NEW HYBRID MOLECULE OF WARFARIN WITH ESSENTIAL ACID | 2018 |
|
RU2677647C1 |
| ANTICOAGULANT AGENT OF INDIRECT ACTION ON BASIS OF DIUMANCAL | 2018 |
|
RU2671983C9 |
| IMMUNOMODULATORY AND ANTIVIRAL AGENT BASED ON (2-((COUMARIN-7-YL)OXY)ETHYL) 3-HYDROXY-20(29)-LUPEN-28-OATE | 2018 |
|
RU2686743C1 |
| ANTIARRHYTHMIC DRUG BASED ON HYBRID MOLECULES OF AMLODIPINE WITH (7-METHOXICUMARIN-4-YL)ACETIC ACID | 2018 |
|
RU2678969C1 |
| DERIVATIVES OF 2-H-1-BENZOPYRANE-2-ONE ELICITING ANTI-CALCIUM ACTIVITY | 2003 |
|
RU2242471C1 |
| COPOLYMERS OF N-VINYLPYRROLIDONE WITH DERIVATIVES OF 5,6-BENZO-ALPHA-PYRONE POSSESSSING ANTIGEN PROPERTIES | 0 |
|
SU1034383A1 |
| 3-O-PROPIONATE ALLOBETULENOLE (19BETA,28-EPOXY-18ALPHA-OLEANANE-3BETA-YL AND PROPIONATE) IMMUNOMODULATORY AGENT | 2013 |
|
RU2554475C2 |
| AGENT FOR TREATMENT OF PATIENT WITH HEART ISCHEMIC DISEASE | 1998 |
|
RU2155036C2 |
| MEDICAMENT WITH PROLONGED ANTI-CALCIUM ACTIVITY IN THE FORM OF 1/10% INTRAVENOUS SOLUTION | 2004 |
|
RU2255728C1 |
| METHOD OF PREPARING DIUMANCAL-FORTE TABLETS IN DOSE 0,01 G | 2000 |
|
RU2187303C2 |
